insitro

The Opportunity

The heart of insitro’s strategy is the development of novel, cutting edge methods in machine learning and high-throughput biology to address key bottlenecks in the drug development pipeline.  As a High-throughput Biology (HTB) intern, you will work with a dynamic team to develop cutting edge molecular biology tools including genetic editing, viral delivery, molecular cloning, next-gen sequencing, and image phenotyping to model human diseases and discover drugs.  We are looking for motivated and talented candidates who are interested in being part of a unique, cross-disciplinary team of biologists, bioengineers, machine learning engineers, and data scientists who want to make a difference. You will be joining as the founding team of a biotech startup that has long-term stability due to significant funding, yet is very much in formation providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us and help make a difference to patients! 

About You

• B.S. or college students majoring in biological science, bio/chemical engineering, or equivalent experience
• 1-4 years of relevant research experience
• Experience in molecular biology, cell culture, genomics and/or microscopy, and viral transduction
• Excellent lab practice/organization and communication 

Nice to Have

• Experience with genetic perturbation and screening technology
• Experience with automation
• Experience developing high-throughput assays with a focus on molecular biology 
• Familiarity with microscopy
• Familiarity with data analysis in Python, R

Benefits at insitro

• Excellent medical, dental, and vision coverage
• Open vacation policy
• Team lunches (catered daily)
• Commuter benefits
• Paid parental leave

About insitro

insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH, a collaboration with BMS in the area of ALS, and in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com